Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 46.0 | 49 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 196.5 | 46 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 262.5 | 54 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 52.0 | 72 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 50.5 | 62 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 69.5 | 58 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 66.0 | 52 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 454.5 | 44 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 475.5 | 42 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 99.0 | 49 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | b-NGF | 83.5 | 48 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 35.0 | 67 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 29.5 | 64 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 131.0 | 49 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 162.0 | 52 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 35.5 | 58 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 33.0 | 43 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 44.5 | 52 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | b-NGF | 46.5 | 64 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 319.5 | 46 | |
N2645 | TNF-a | 100 | ng/mL | 4 | b-NGF | 348.0 | 50 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | b-NGF | 66.0 | 44 | |
RA2708 | TNF-a | 100 | ng/mL | 4 | b-NGF | 63.0 | 42 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 4 | b-NGF | 30.0 | 47 | ||||
RA2159 | IKK16 | 2.0 | uM | 4 | b-NGF | 20.0 | 45 |